Recombinant growth hormone therapy for prepubertal children with idiopathic short stature in Korea: a phase III randomized trial

ConclusionsOne-year GH treatment for prepubertal children with ISS demonstrated increased annualized velocity, height and weight SDSs, and IGF-1 and IGFBP-3 levels, with a favorable safety profile. Further evaluations are needed to determine the optimal dose, final adult height, and long-term effects of ISS treatment.

http://link.springer.com/10.1007/s40618-017-0786-8

Source: Journal of Endocrinological Investigation - November 4, 2017 Category: Endocrinology Source Type: research